Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2026 | Current and emerging systemic strategies in biochemically relapsed prostate cancer

Ashwin Sachdeva • 16 May 2026
ESTRO 2026
Genitourinary Cancer Prostate Cancer

Ashwin Sachdeva, MBBS, PhD, University of Manchester, Manchester, UK, explores current and emerging systemic therapies with salvage radiotherapy for the treatment biochemically relapsed prostate cancer. Dr Sachdeva highlights key areas of research, including androgen deprivation therapy (ADT) in patients with higher-risk biochemical relapse, ADT and androgen receptor pathway inhibitors (ARPI) in patients not eligible for salvage radiotherapy, perioperative systemic therapy in patients with a high-risk of relapse and the future of biomarker-directed treatment. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
The content of VJOncology is intended for healthcare professionals